New licensed treatment for premature ejaculation
Dapoxetine (Priligy) has been licensed for use in men who have been diagnosed with premature ejaculation.
Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI). SSRIs are sometimes used off-label to treat premature ejaculation on the basis of their side-effect of delayed ejaculation. They act by inhibiting reuptake of serotonin into the presynaptic neuron, thereby potentiating the activity of the neurotransmitter. Unlike existing SSRIs, dapoxetine has a rapid onset of action, which makes it suitable for on-demand treatment.
The recommended starting dose is 30mg, which should be taken 1 to 3 hours prior to sexual activity. It should be taken on a “when required” basis and doses must not be repeated within 24 hours.
If the individual response to 30mg is insufficient and the patient has not experienced moderate or severe adverse reactions or prodromal symptoms suggestive of syncope, the dose may be increased to a maximum recommended dose of 60mg taken as needed approximately 1 to 3 hours prior to sexual activity. The incidence and severity of adverse events is higher with the 60mg dose.
Adverse events, most commonly nausea, dizziness, diarrhoea and headache, led to discontinuation in 3.9% of patients taking dapoxetine 30mg, 8.2% of patients taking dapoxetine 60mg and 1.3% of those receiving placebo.
Photo by Ragesoss (Own work) [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0) or GFDL (http://www.gnu.org/copyleft/fdl.html)], via Wikimedia Commons